hero image

Biogen Announces 2023 Annual Shareholder Meeting Preliminary Results

June 26, 2023 Company Statements

Cambridge, Mass. – June 26, 2023Biogen Inc. (Nasdaq: BIIB) today held its Annual Meeting of shareholders. As previously announced, Caroline Dorsa has succeeded Stelios Papadopoulos as Chair of the Board of Directors at conclusion of the Annual Meeting. Preliminary results indicate that shareholders reelected the Company’s 7 director nominees to one-year terms and elected Susan Langer as a Director.

A majority of shareholders also voted in favor of the advisory vote on the Company’s executive compensation and approved “one year” for the frequency of the advisory vote on executive compensation. Lastly, shareholders voted to ratify the selection of PricewaterhouseCoopers LLP as Biogen Inc.’s independent registered public accounting firm for the fiscal year ending December 31, 2023.

“We thank our shareholders for their participation and engagement in today’s Annual Meeting. 2022 was an important year for Biogen, and we aim to build on our momentum to continue to innovate life-changing medicines for patients worldwide. In addition, we thank our departing board members – including Board Chair Stelios Papadopoulos, Alexander J. Denner, Ph.D., William D. Jones, and Richard C. Mulligan, Ph.D., – for their years of service to Biogen and the biotech industry,” said Caroline Dorsa, Chair of the Biogen Board of Directors.

Final voting results are subject to verification by the independent inspector of election and will be reported on a Current Report on Form 8-K to be filed with the U.S. Securities and Exchange Commission within four business days.

About Biogen

Founded in 1978, Biogen is a leading global biotechnology company that has pioneered multiple breakthrough innovations including a broad portfolio of medicines to treat multiple sclerosis, the first approved treatment for spinal muscular atrophy, and two co-developed treatments to address a defining pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, neuropsychiatry, specialized immunology and rare diseases and remains acutely focused on its purpose of serving humanity through science while advancing a healthier, more sustainable and equitable world.

We routinely post information that may be important to investors on our website at www.biogen.com. Follow us on social media - TwitterLinkedInFacebookYouTube.

Biogen Safe Harbor 

This press release contains forward-looking statements, relating to: our strategy and plans; potential of, and expectations for, our commercial business, pipeline programs and clinical development programs. These forward-looking statements may be accompanied by such words as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “potential,” “possible,” “prospect,” “will,” “would,” and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements.

These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including: our dependence on sales from our products; uncertainty of long-term success in developing, licensing, or acquiring other product candidates or additional indications for existing products; failure to compete effectively due to significant product competition in the markets for our products; failure to successfully execute or realize the anticipated benefits of our strategic and growth initiatives; difficulties in obtaining and maintaining adequate coverage, pricing, and reimbursement for our products; our dependence on collaborators, joint venture partners, and other third parties for the development, regulatory approval, and commercialization of products and other aspects of our business, which are outside of our full control; the potential impact of the conflict in Ukraine; risks associated with current and potential future healthcare reforms; risks related to commercialization of biosimilars; failure to obtain, protect, and enforce our data, intellectual property, and other proprietary rights and the risks and uncertainties relating to intellectual property claims and challenges; the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in early stage clinical trials may not be predictive of results in later stage or large scale clinical trials or trials in other potential indications; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; the occurrence of adverse safety events, restrictions on use with our products, or product liability claims; risks relating to technology failures or breaches; problems with our manufacturing processes; risks relating to management and personnel changes, including attracting and retaining personnel; failure to comply with legal and regulatory requirements; the risks of doing business internationally, including currency exchange rate fluctuations; risks relating to investment in our manufacturing capacity; the direct and indirect impacts of the ongoing COVID-19 pandemic on our business; risks relating to the distribution and sale by third parties of counterfeit or unfit versions of our products; risks relating to the use of social media for our business; results of operations, and financial condition; fluctuations in our operating results; risks related to investment in properties; the market, interest, and credit risks associated with our investment portfolio; risks relating to share repurchase programs; risks relating to access to capital and credit markets; risks related to indebtedness; change in control provisions in certain of our collaboration agreements; fluctuations in our effective tax rate; environmental risks; and any other risks and uncertainties that are described in other reports we have filed with the U.S. Securities and Exchange Commission. These statements speak only as of the date of this press release. We do not undertake any obligation to publicly update any forward-looking statements.

 

 

MEDIA CONTACT:

Biogen

Jack Cox

+ 1 781 464 3260

public.affairs@biogen.com

 

 

 

 

 

 

 

INVESTOR CONTACT:

Biogen

Chuck Triano

+1 781 464 2442

IR@biogen.com  

 

 

 

 

 

 

 

thumb
April 24, 2024
BIOGEN TO REPORT FIRST QUARTER 2024 FINANCIAL RESULTS APRIL 24, 2024

Cambridge, Mass.— Biogen Inc . (Nasdaq:BIIB) today announced it will report first quarter 2024 financial results Wednesday, April 24, 2024, before the financial markets open. Following the release of the financials, the Company will host a live webcast with Biogen management at 8:30 a.m. ET.

thumb
March 31, 2024
Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease to the U.S. FDA

TOKYO and CAMBRIDGE, Mass., April 1, 2024 – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that Eisai submitted to the U.S.